Diffuse Large B-cell Lymphoma Market Set to Grow Substantially Through 2034, DelveInsight Projects | Genmab and AbbVie, Kite (Gilead Sciences), Denovo Biopharma, Merck

The Key Diffuse Large B-cell Lymphoma Companies in the market include - Ubix Therapeutics, Otsuka Pharmaceutical Co., Ltd, Biomea Fusion Inc, Autolus Limited, Xynomic Pharmaceuticals, Inc., Hanmi Pharmaceutical, S IMV Inc. Seagen Inc., Zai Lab, Genentech, and others.
DelveInsight's "Diffuse Large B-cell Lymphoma Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Diffuse Large B-cell Lymphoma, historical and forecasted epidemiology as well as the Diffuse Large B-cell Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Diffuse Large B-cell Lymphoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Diffuse Large B-cell Lymphoma Market Forecast [https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Diffuse Large B-cell Lymphoma Market Report:

*
The Diffuse Large B-cell Lymphoma market size was valued ~USD 3,900 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).

*
In September 2025, Phase II EPCORE NHL-6 trial results indicated that Genmab's and AbbVie's Epkinly (epcoritamab) showed promising efficacy in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who had undergone at least one prior systemic therapy. The companies noted that the trial underscores the potential for outpatient administration of Epkinly, which may expand treatment accessibility and provide a more convenient, flexible option for managing R/R DLBCL.

*
In July 2025, Results from the Phase Ib trial (NCT03666000) indicated that Imugene's azer-cel (azercabtagene zapreleucel), an off-the-shelf allogeneic CAR-T therapy, showed substantial promise in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company stated it intends to request a Type B meeting with the FDA in Q4 to discuss the design of a registrational trial, supported by the robust data and the therapy's Fast Track Designation granted in March.

*
In May 2025, Merck & Co (MSD)'s antibody-drug conjugate, zilovertamab vedotin, developed for the treatment of diffuse large B-cell lymphoma (DLBCL), has shown encouraging results in a Phase II/III clinical trial, positioning the company to potentially rival ADC Therapeutics' already approved therapy.

*
In March 2025, The FDA has granted Fast Track designation to azer-cel, an allogeneic, off-the-shelf CD19-targeted CAR T-cell therapy, for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Currently, a Phase 1b clinical trial (NCT03666000) is ongoing to assess azer-cel in individuals with relapsed or refractory non-Hodgkin lymphoma or B-cell acute lymphoblastic leukemia. This multicenter, open-label, nonrandomized trial involves dose escalation and expansion to evaluate the safety and clinical efficacy of the therapy in patients with CD19-positive relapsed/refractory B-cell non-Hodgkin lymphoma.

*
In February 2025, Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, has launched waveLINE-010, a pivotal Phase 3 clinical trial assessing zilovertamab vedotin in combination with rituximab plus cyclophosphamide, doxorubicin, and prednisone (R-CHP) against rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for previously untreated diffuse large B-cell lymphoma (DLBCL). Zilovertamab vedotin is Merck's investigational antibody-drug conjugate (ADC) designed to target receptor tyrosine kinase-like orphan receptor 1 (ROR1).

*
In December 2024, Genmab A/S (Nasdaq: GMAB) has reported new long-term results from two ongoing clinical trials investigating epcoritamab, a subcutaneous T-cell engaging bispecific antibody, in adult patients with diffuse large B-cell lymphoma (DLBCL). In Arm 1 of the Phase 1b/2 EPCORE Registered NHL-2 trial (NCT04663347), a fixed-duration regimen of epcoritamab combined with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) achieved a 100% overall response rate (ORR) and an 87% complete response (CR) rate in high-risk, previously untreated DLBCL patients (n=46). Among complete responders, 83% remained in remission after two years. Meanwhile, results from the Phase 2 EPCORE Registered NHL-1 trial (NCT03625037), evaluating epcoritamab monotherapy in difficult-to-treat adults with relapsed or refractory (R/R) large B-cell lymphoma (LBCL; including 148 R/R DLBCL patients), revealed that 41% achieved a CR, with an estimated 52% of these responders maintaining remission after three years (median CR duration: 36.1 months).

*
In November 2024, Novotech, a leading global full-service clinical Contract Research Organization (CRO) specializing in partnering with biotech companies to expedite the development of innovative therapeutics across all phases, has unveiled new insights into the global clinical trial landscape for Diffuse Large B-Cell Lymphoma (DLBCL), solidifying its prominence in oncology research.

*
In June 2024, Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced significant and clinically meaningful findings from the Phase III STARGLO study of Columvi Registered (glofitamab) combined with gemcitabine and oxaliplatin (GemOx). The study compared this combination to MabThera Registered /Rituxan Registered (rituximab) with GemOx (R-GemOx) in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have undergone at least one prior therapy and are ineligible for autologous stem cell transplant or have received two or more prior treatments. The data was highlighted during a press briefing and presented as a late-breaking oral presentation in the Plenary Abstracts Session at the European Hematology Association (EHA) 2024 Congress.

*
The total market size for Diffuse Large B-Cell Lymphoma in the US was estimated at around USD 2,000 million in 2023 and is projected to grow throughout the forecast period from 2024 to 2034.

*
DelveInsight estimates that in 2023, there were around 17,000 cases of Diffuse Large B-Cell Lymphoma (DLBCL) in males in the United States.

*
In the United States, the highest number of DLBCL patients is found in the 65-74 age group, while the lowest number is in the 0-19 age group.

*
According to the analysis, Stage IV represents the highest number of DLBCL cases, with approximately 12,000 cases, followed by Stage I in 2023 in the US.

*
Approved drugs for the treatment of Diffuse Large B-Cell Lymphoma include RITUXAN/MABTHERA (rituximab), YESCARTA (axicabtagene ciloleucel), KYMRIAH (tisagenlecleucel), XPOVIO (selinexor), POLIVY (polatuzumab vedotin-piiq), KEYTRUDA (pembrolizumab), COLUMVI (glofitamab), EPKINLY (epcoritamab), among others .

*
Key Diffuse Large B-cell Lymphoma Companies: Ubix Therapeutics, Otsuka Pharmaceutical Co., Ltd, Biomea Fusion Inc, Autolus Limited, Xynomic Pharmaceuticals, Inc., Hanmi Pharmaceutical, S IMV Inc. Seagen Inc., Zai Lab, Genentech, and others

*
Key Diffuse Large B-cell Lymphoma Therapies: UBX-303, OPB-111077, BMF-219, AUTO3, Abexinostat, Poseltinib, Maveropepimut, Brentuximabvedotin, Odronextamab, Mosunetuzumab, and others

*
The Diffuse Large B-cell Lymphoma epidemiology based on gender analyzed that Males have higher incident cases of Diffuse Large B-cell Lymphoma as compared to females

*
The Diffuse Large B-cell Lymphoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Diffuse Large B-cell Lymphoma pipeline products will significantly revolutionize the Diffuse Large B-cell Lymphoma market dynamics.

Diffuse Large B-cell Lymphoma Overview

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) that develops when B-lymphocytes become abnormal. It arises from the germinal center and post germinal center B-cells. The etiology of DLBCL is complex and multifactorial. DLBCL can arise de-novo or from the transformation of indolent diseases like chronic lymphocytic lymphoma/small lymphocytic lymphoma (so-called Richter's transformation), follicular lymphoma, and marginal zone lymphoma

Get a Free sample for the Diffuse Large B-cell Lymphoma Market Report -

https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-market [https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Diffuse Large B-cell Lymphoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Diffuse Large B-cell Lymphoma Epidemiology Segmentation:

The Diffuse Large B-cell Lymphoma market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Diffuse Large B-cell Lymphoma

*
Prevalent Cases of Diffuse Large B-cell Lymphoma by severity

*
Gender-specific Prevalence of Diffuse Large B-cell Lymphoma

*
Diagnosed Cases of Episodic and Chronic Diffuse Large B-cell Lymphoma

Download the report to understand which factors are driving Diffuse Large B-cell Lymphoma epidemiology trends @ Diffuse Large B-cell Lymphoma Epidemiology Forecast [https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Diffuse Large B-cell Lymphoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Diffuse Large B-cell Lymphoma market or expected to get launched during the study period. The analysis covers Diffuse Large B-cell Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Diffuse Large B-cell Lymphoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Diffuse Large B-cell Lymphoma Therapies and Key Companies

*
UBX-303: Ubix Therapeutics

*
OPB-111077: Otsuka Pharmaceutical Co., Ltd

*
BMF-219: Biomea Fusion Inc

*
AUTO3: Autolus Limited

*
Abexinostat: Xynomic Pharmaceuticals, Inc.

*
Poseltinib: Hanmi Pharmaceutical

*
Maveropepimut: S IMV Inc.

*
Brentuximabvedotin: Seagen Inc.

*
Odronextamab: Zai Lab

*
Mosunetuzumab: Genentech

Discover more about therapies set to grab major Diffuse Large B-cell Lymphoma market share @ Diffuse Large B-cell Lymphoma Treatment Market [https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Diffuse Large B-cell Lymphoma Market Strengths

*
The incidence of lymphomas has increased in recent years leading to more focus by pharmaceutical firms

*
The understanding of the biology of DLBCL has increased in the last years and has allowed a better understanding of the molecular mechanisms underlying the disease

Diffuse Large B-cell Lymphoma Market Opportunities

*
Rituximab dominates the market in front-line settings, and there is still scope for other drugs in these settings with or without rituximab

*
The recent development in artificial intelligence (AI) technology has shown promising results in reducing labor of pathologists and improving diagnostic accuracy, thus improving the market landscape

Scope of the Diffuse Large B-cell Lymphoma Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Diffuse Large B-cell Lymphoma Companies: Ubix Therapeutics, Otsuka Pharmaceutical Co., Ltd, Biomea Fusion Inc, Autolus Limited, Xynomic Pharmaceuticals, Inc., Hanmi Pharmaceutical, S IMV Inc. Seagen Inc., Zai Lab, Genentech, and others

*
Key Diffuse Large B-cell Lymphoma Therapies: UBX-303, OPB-111077, BMF-219, AUTO3, Abexinostat, Poseltinib, Maveropepimut, Brentuximabvedotin, Odronextamab, Mosunetuzumab, and others

*
Diffuse Large B-cell Lymphoma Therapeutic Assessment: Diffuse Large B-cell Lymphoma current marketed and Diffuse Large B-cell Lymphoma emerging therapies

*
Diffuse Large B-cell Lymphoma Market Dynamics: Diffuse Large B-cell Lymphoma market drivers and Diffuse Large B-cell Lymphoma market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Diffuse Large B-cell Lymphoma Unmet Needs, KOL's views, Analyst's views, Diffuse Large B-cell Lymphoma Market Access and Reimbursement

To know more about Diffuse Large B-cell Lymphoma companies working in the treatment market, visit @ Diffuse Large B-cell Lymphoma Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Diffuse Large B-cell Lymphoma Market Report Introduction

2. Executive Summary for Diffuse Large B-cell Lymphoma

3. SWOT analysis of Diffuse Large B-cell Lymphoma

4. Diffuse Large B-cell Lymphoma Patient Share (%) Overview at a Glance

5. Diffuse Large B-cell Lymphoma Market Overview at a Glance

6. Diffuse Large B-cell Lymphoma Disease Background and Overview

7. Diffuse Large B-cell Lymphoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Diffuse Large B-cell Lymphoma

9. Diffuse Large B-cell Lymphoma Current Treatment and Medical Practices

10. Diffuse Large B-cell Lymphoma Unmet Needs

11. Diffuse Large B-cell Lymphoma Emerging Therapies

12. Diffuse Large B-cell Lymphoma Market Outlook

13. Country-Wise Diffuse Large B-cell Lymphoma Market Analysis (2020-2034)

14. Diffuse Large B-cell Lymphoma Market Access and Reimbursement of Therapies

15. Diffuse Large B-cell Lymphoma Market Drivers

16. Diffuse Large B-cell Lymphoma Market Barriers

17. Diffuse Large B-cell Lymphoma Appendix

18. Diffuse Large B-cell Lymphoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=diffuse-large-bcell-lymphoma-market-set-to-grow-substantially-through-2034-delveinsight-projects-genmab-and-abbvie-kite-gilead-sciences-denovo-biopharma-merck]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.